Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 14;20(26):8407-15.
doi: 10.3748/wjg.v20.i26.8407.

Nonalcoholic fatty liver disease and cardiovascular disease

Hong Liu  1 , Hong-Yun Lu  1
Affiliations
Review

Nonalcoholic fatty liver disease and cardiovascular disease

Hong Liu et al. World J Gastroenterol. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are two diseases that are common in the general population. To date, many studies have been conducted and demonstrate a direct link between NAFLD and CVD, but the exact mechanisms for this complex relationship are not well established. A systematic search of the PubMed database revealed that several common mechanisms are involved in many of the local and systemic manifestations of NAFLD and lead to an increased cardiovascular risk. The possible mechanisms linking NAFLD and CVD include inflammation, oxidative stress, insulin resistance, ectopic adipose tissue distribution, dyslipidemia, endothelial dysfunction, and adiponectin, among others. The clinical implication is that patients with NAFLD are at an increased risk of CVD and should undergo periodic cardiovascular risk assessment.

Keywords: Cardiovascular disease; Metabolic syndrome; Nonalcoholic fatty liver disease; Risk assessment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evaluated treatments for nonalcoholic fatty liver disease. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.
See this image and copyright information in PMC

References

    1. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts. Acta Med Okayama. 2013;67:45–53. - PubMed
    1. Blackett PR, Sanghera DK. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J Clin Lipidol. 2013;7:65–81. - PMC - PubMed
    1. Nestel PJ, Mensink RP. Perspective: nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol. 2013;24:1–3. - PubMed
    1. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84–129. - PubMed
    1. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, Agladioglu K, Yeniova AO, Nazligul Y, Ertugrul DT. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013;25:147–151. - PubMed

MeSH terms